Global Infectious Vaccines Market Size By Type (Preventive vaccine, Therapeutic vaccine), By Application (Adults, Pediatrics), By Region, And Segment Forecasts, 2023 to 2032

The Global Infectious Vaccines Market was valued at USD 64.7 billion in 2023 and is projected to reach USD 103.9 billion by 2031, growing at a CAGR of 6.2% during the forecast period from 2023 to 2031. The market growth is driven by increasing awareness about vaccine-preventable diseases, growing governmental and non-governmental immunization initiatives, and a strong pipeline of new vaccine candidates. The resurgence of certain infectious diseases and the emergence of new pathogens further underline the critical role of vaccines in global public health management.

Drivers:

1. Rising Incidence of Infectious Diseases

The increasing prevalence of infectious diseases such as influenza, hepatitis, tuberculosis, and newly emerging pathogens like SARS-CoV-2 has bolstered demand for preventive immunization strategies worldwide.

2. Government and NGO Support

Robust immunization campaigns by WHO, GAVI, and national public health agencies, coupled with funding and logistical support, have significantly improved vaccine access in both developed and developing countries.

3. Advancements in Vaccine Technology

Innovations such as mRNA technology, vector-based vaccines, and thermostable formulations are improving vaccine efficacy, shelf life, and distribution, driving market expansion.

Restraints:

1. High Cost of Vaccine Development

Developing a new vaccine involves substantial investments in research, clinical trials, and regulatory approvals, which can deter smaller manufacturers.

2. Vaccine Hesitancy and Misinformation

Public skepticism, driven by misinformation and cultural beliefs, can limit vaccine uptake in certain regions, affecting immunization coverage rates.

Opportunity:

1. Growth in Emerging Markets

Emerging economies in Asia-Pacific and Africa are investing in healthcare infrastructure and launching universal immunization programs, creating substantial growth opportunities for vaccine manufacturers.

2. Technological Integration and Personalized Vaccines

Digital health integration for immunization tracking and the rise of personalized vaccine approaches present new avenues for innovation and market penetration.

Market by System Type Insights:

Based on the type of vaccine system, the Live Attenuated Vaccines segment dominated the market in 2023. These vaccines offer long-lasting immunity and are commonly used for diseases such as measles, mumps, and rubella. However, the mRNA-based Vaccines segment is projected to witness the fastest growth rate, driven by the success of COVID-19 mRNA vaccines and the continued development of mRNA platforms for other infectious diseases.

Market by End-use Insights:

In terms of end-use, the Pediatric segment accounted for the largest market share in 2023, reflecting the high volume of childhood immunizations worldwide. However, the Adult & Geriatric segment is expected to grow significantly, supported by increasing vaccination coverage for influenza, shingles, and COVID-19 among older adults.

Market by Regional Insights:

North America led the global infectious vaccines market in 2023, driven by high healthcare spending, established immunization infrastructure, and strong R&D activities. Asia-Pacific is anticipated to register the highest CAGR during the forecast period, fueled by large population bases, rising health awareness, and expanding vaccination programs in countries such as India and China.

Competitive Scenario:

Key players in the Global Infectious Vaccines Market include Pfizer Inc., GlaxoSmithKline plc, Sanofi, Moderna Inc., Merck & Co., Inc., Johnson & Johnson, AstraZeneca plc, Bharat Biotech, CSL Limited, and Sinovac Biotech Ltd. These companies are actively investing in clinical trials, forging strategic partnerships, and expanding their production capacities to meet growing global demand.

Key Developments:

2023: Moderna announced a global expansion of its mRNA vaccine pipeline to include vaccines for influenza, RSV, and HIV.

2024: Pfizer launched its updated pneumococcal conjugate vaccine covering more serotypes for enhanced adult protection.

2025: Sanofi and GSK received regulatory approval for their co-developed recombinant COVID-19 booster vaccine.

Scope of Work – Global Infectious Vaccines Market

FAQs:

1) What is the current market size of the Global Infectious Vaccines Market?

The market was valued at USD 64.7 billion in 2023.

2) What is the major growth driver of the Global Infectious Vaccines Market?

The rising incidence of infectious diseases and advancements in vaccine technology are key growth drivers.

3) Which is the largest region during the forecast period in the Global Infectious Vaccines Market?

North America currently leads, but Asia-Pacific is projected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Infectious Vaccines Market?

The Pediatric segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Infectious Vaccines Market?

Major players include Pfizer, Moderna, GSK, Sanofi, Merck, Johnson & Johnson, and AstraZeneca.